Systemic Dickkopf-related Protein 1 (DKK1)During Estrogen Level Changes in Post-menopausal Breast Cancer Patients Treated With Aromatase Inhibitors
Breast Cancer
Conditions: official terms
Breast Neoplasms
Conditions: Keywords
Aromatase Inhibitors
Study Type
Study Phase
Study Design
Observational Model: Cohort, Time Perspective: Prospective
Overall Status
The investigators are hypothesizing that decreasing estrogen levels will cause serum DKK1 to peak, then decrease gradually as estrogens reach a new lower, but steady level. The investigators also believe that the peak in DKK1 will initiated a wave of stem cell diversion from the osteoblastogenic pathway to the adipogenic pathway.

The investigators will conduct a longitudinal cohort study of post menopausal women with hormone-responsive breast cancer that will be treated AIs. The study will observe anthromorphic and serum marker changes during the first year of their treatment.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Female
Criteria: Inclusion Criteria:

- Post Menopausal Breast cancer patients with planned treatment of aromatase inhibitors.

- 18 years or older

Exclusion Criteria:

- BMI >30 or <18

- Osteoporosis as defined by protocol.

- Subjects currently on bisphosphonate therapy.

- History of primary or secondary hyperparathyroidism

- History of Hypo-or Hyperthyroidism

- History of Vitamin D levels below LLN

- History of creatinine clearance below the EGFR

- History ofLiver function tests above 1.5 times ULN including LDH, SGOT, SGPT, Alkaline phosphatase, and Bilirubin

- History of documented cirrhosis of the liver

- History of chronic heparin use

- History of chronic glucocorticoid therapy
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
Status: Recruiting
Contact: Cindy Walton - 501-686-8274 -
Start Date
April 2011
Completion Date
September 2015
University of Arkansas
University of Arkansas
Record processing date processed this data on July 28, 2015 page